Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · ImageneBio, Inc. (IMA)

ImageneBio Q3 2026 net loss narrows to $15.6 million from $24.8 million

Positive Impact 3 of 5 earnings

ImageneBio reported third quarter 2026 results, with a net loss of $15.6 million, or $0.91 per share, down from $24.8 million, or $2.91 per share, a year earlier. The company had no revenue in either period, and lower research and development and general and administrative expenses drove the smaller loss. It ended the quarter with $126.6 million in cash, cash equivalents and marketable securities, which it expects will fund planned operations into the first quarter of 2028.

Key points

  • Net loss was $15.6 million for the three months ended September 30, 2026, compared with $24.8 million a year earlier.
  • Net loss per share was $0.91, compared with $2.91 a year earlier.
  • R&D expenses fell to $11.3 million from $15.2 million, and G&A expenses fell to $6.0 million from $11.0 million.
  • Cash position was $126.6 million as of September 30, 2026, with funding expected into the first quarter of 2028.

The filing

CompanyImageneBio, Inc. (IMA)
Form8-K, current report
Filed with the SECNov 9, 2026, 4:17 PM ET
Accession number0001193125-26-453639

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 6:16 PM ET, from this filing only.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.